The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its Board officers for 2026, following elections held during the organization’s December 2025 Board meeting. The announcement marks a significant milestone for the relatively young global initiative, which continues to position itself at the forefront of efforts to replace animal testing in cosmetics safety assessment with scientifically robust, human-relevant alternatives. The newly elected leadership reflects both continuity and growing maturity within ICCS, as the organization builds on a year of substantial progress and looks ahead to expanding its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collaboration, bringing together diverse stakeholders who share a common objective: accelerating the global adoption and acceptance of animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers underscores the organization’s intention to maintain strategic focus while navigating an increasingly complex international landscape, where expectations for ethical research, scientific rigor, and regulatory alignment continue to evolve.
Leadership continuity and global representation
The 2026 Board leadership brings together senior figures from across the cosmetics, consumer products, and regulatory advocacy sectors, reflecting the multi-stakeholder nature that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been re-elected as Chair of the Board of Directors. His reappointment signals confidence in a leadership approach that has emphasized scientific credibility, global cooperation, and constructive engagement with regulators.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose long-standing work in industry advocacy and regulatory engagement provides a strong regional and policy-driven outlook. The role of Secretary will be fulfilled by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing broad expertise in regulatory toxicology and global product safety systems. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been appointed Treasurer, offering substantial leadership experience in toxicology and governance.
Acting collectively, the officers make up a Board leadership team whose experience extends across multinational corporations, industry groups, and regulatory science, strengthening ICCS’ role as a neutral forum for cooperation rather than an advocate for any particular sector. This equilibrium underpins the organization’s credibility, especially as it works to shape regulatory perspectives and promote alignment on animal-free safety approaches.
Advancing animal-free science through collaboration
At the heart of ICCS’ mission is the belief that animal-free approaches to safety assessment are not only ethically preferable but scientifically superior when properly developed and validated. Since its formation in early 2023, ICCS has worked to demonstrate that non-animal methods can provide reliable, relevant information for protecting both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining traction, supported by tangible outputs and growing engagement from regulators around the world.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
Equally important has been the organization’s emphasis on dialogue. Throughout 2025, ICCS engaged extensively with regulators, scientists, and policymakers across multiple regions, contributing to discussions on how animal-free data can be interpreted and accepted within existing regulatory frameworks. These conversations have been instrumental in building shared understanding and trust, particularly in jurisdictions where regulatory acceptance of non-animal methods is still developing.
A defining turning point in cosmetics safety oversight
The appointment of the 2026 Board officers takes place against a backdrop of significant change in global cosmetics regulation. Many markets are reassessing long-standing testing requirements, responding to public expectations, scientific advances, and international policy trends. In this context, organizations like ICCS play a critical role in helping align innovation with regulation, ensuring that progress is both credible and sustainable.
ICCS leadership has consistently emphasized that the transition to animal-free safety science cannot be achieved through isolated efforts. Instead, it requires coordinated action across industry, academia, regulators, and civil society. The composition of the Board reflects this philosophy, bringing together leaders who understand the technical, regulatory, and organizational dimensions of change.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair highlighted how crucial it is to draw on ICCS’ global, multi-stakeholder framework to narrow the distance between innovation and regulation, ensuring that progress in animal-free science moves beyond laboratories and becomes reliable, consistently applied tools that regulators can confidently use.
Reinforcing the groundwork for lasting impact
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education continues to be a central pillar of ICCS’ strategy, with the organization striving to offer accessible, science‑grounded materials and spaces for dialogue that help clarify the principles of animal‑free safety science and support well‑informed choices. This effort becomes especially vital in a field where misunderstandings or uneven levels of expertise can hinder advancement, even when the science itself is robust.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Based in New York, ICCS remains active as a worldwide initiative, underscoring the global character of cosmetic innovation and regulatory oversight. As products and their ingredients circulate internationally, coordinated standards and mutual acknowledgment of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science across the globe.
In confirming its 2026 Board officers, ICCS conveys steadiness while signaling continued progress, with its leadership team offering consistent guidance after a year of tangible accomplishments and the seasoned insight required to steer the upcoming phase of transformation; as scientific advances accelerate and regulatory expectations shift, the organization’s function as a convening force and driving agent for animal-free cosmetics safety science is poised to gain even greater significance.
In the end, the importance of the 2026 Board elections stems not only from the members selected but also from what their leadership conveys: an ongoing dedication to cooperation, scientific rigor, and the responsible evolution of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn vision into enduring results, shaping the future of cosmetics safety in a manner that brings ethics, science, and global public confidence into alignment.
